A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patients
M Ayyoub, NE Souleimanian, E Godefroy, L Scotto… - Clinical …, 2006 - Elsevier
Because of its frequent expression in tumors and spontaneous immunogenicity in advanced
cancer patients, NY-ESO-1 is presently viewed as a prototype tumor antigen for the
development of cancer vaccines. A prerequisite for the analysis of NY-ESO-1-specific T cell
responses in vaccinated patients is the assessment of the complete T cell repertoire
available for the antigen. Here, we have assessed frequency and fine specificity of CD4+ T
cells reactive against NY-ESO-1-derived sequences in circulating lymphocytes from cancer …
cancer patients, NY-ESO-1 is presently viewed as a prototype tumor antigen for the
development of cancer vaccines. A prerequisite for the analysis of NY-ESO-1-specific T cell
responses in vaccinated patients is the assessment of the complete T cell repertoire
available for the antigen. Here, we have assessed frequency and fine specificity of CD4+ T
cells reactive against NY-ESO-1-derived sequences in circulating lymphocytes from cancer …